Literature DB >> 3373011

Hairless mouse skin is limited as a model for assessing the effects of penetration enhancers in human skin.

J R Bond1, B W Barry.   

Abstract

The permeability coefficient of 5-fluorouracil through human abdominal and hairless mouse skins was used as an indicator of the relative effects of 12-h pretreatment of the skins with either penetration-enhancer mixtures [including laurocapram (Azone), decylmethylsulfoxide, oleic acid, and propylene glycol] or saline (control). After treatment with saline, fluxes of 5-fluorouracil through the two skin types were similar, but the mouse skin showed exaggerated responses to all the penetration-enhancer formulations. There was no consistent relationship between enchancer effects on the two skin types, and we conclude that the hairless mouse model should not be used to predict the effects of penetration enhancers in human skin. After treatment with saline, hairless mouse skin sharply increased in permeability after approximately 50 h hydration, suggesting that the stratum corneum had started to disrupt, whereas the flux through human skin remained unchanged.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373011     DOI: 10.1111/1523-1747.ep12462031

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Selegiline percutaneous absorption in various species and metabolism by human skin.

Authors:  S Rohatagi; J S Barrett; L J McDonald; E M Morris; J Darnow; A R DiSanto
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

2.  Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.

Authors:  Patrycja Mikolajewska; Ryan F Donnelly; Martin J Garland; Desmond I J Morrow; Thakur Raghu Raj Singh; Vladimir Iani; Johan Moan; Asta Juzeniene
Journal:  Pharm Res       Date:  2010-07-31       Impact factor: 4.200

3.  Transdermal delivery of zidovudine (AZT): the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin.

Authors:  Nuntakan Suwanpidokkul; Phensri Thongnopnua; Kaisri Umprayn
Journal:  AAPS PharmSciTech       Date:  2004-08-18       Impact factor: 3.246

4.  Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement.

Authors:  A C Williams; B W Barry
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

5.  Cutaneous metabolism of nitroglycerin in vitro. II. Effects of skin condition and penetration enhancement.

Authors:  N Higo; R S Hinz; D T Lau; L Z Benet; R H Guy
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

6.  Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport.

Authors:  H K Choi; G L Flynn; G L Amidon
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

7.  Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens.

Authors:  Tiffany C Scharschmidt; Mao-Qiang Man; Yutaka Hatano; Debra Crumrine; Roshan Gunathilake; John P Sundberg; Kathleen A Silva; Theodora M Mauro; Melanie Hupe; Soyun Cho; Yan Wu; Anna Celli; Matthias Schmuth; Kenneth R Feingold; Peter M Elias
Journal:  J Allergy Clin Immunol       Date:  2009-09       Impact factor: 10.793

8.  Enhancement of the in vitro skin permeability of azidothymidine (AZT) via iontophoresis and chemical enhancer.

Authors:  L Wearley; Y W Chien
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

Review 9.  Nanoparticles for transcutaneous vaccination.

Authors:  Steffi Hansen; Claus-Michael Lehr
Journal:  Microb Biotechnol       Date:  2011-08-19       Impact factor: 5.813

10.  Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966.

Authors:  Maria Lapteva; Sergio Del Río-Sancho; Eric Wu; W Shawn Carbonell; Christof Böhler; Yogeshvar N Kalia
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.